| 引用本文:侯爱画1，刘伟1，谭松1，戴玲玲1，张金波2.矾贝散结颗粒辅助表皮生长因子受体-酪氨酸酶抑制剂靶向治疗晚期肺腺癌的临床疗效及对免疫功能的影响[J].世界中医药,2018,(07):. |
|
| 矾贝散结颗粒辅助表皮生长因子受体-酪氨酸酶抑制剂靶向治疗晚期肺腺癌的临床疗效及对免疫功能的影响 |
| Clinical Efficacy of Fanbei Sanjie Granule Assisted EGFR-TKI on Advanced Lung Adenocarcinoma and Effects on Immune Function |
| 投稿时间：2017-05-03 |
| DOI：10.3969/j.issn.1673-7202.2018.07.035 |
| 中文关键词: 晚期肺腺癌 矾贝散结颗粒 中医 生命质量 疗效 |
| English Keywords:Advanced lung adenocarcinoma Fanbei Sanjie Granule Traditional Chinese medicine Quality of life Efficacy |
| 基金项目:烟台市科技局项目（2016WS049） |
|
| 摘要点击次数: 1265 |
| 全文下载次数: 1084 |
| 中文摘要: |
| 目的：探讨矾贝散结颗粒辅助表皮生长因子受体-酪氨酸酶抑制剂(EGFR-TKI)靶向治疗晚期肺腺癌的临床疗效及对免疫功能的影响。方法：选取2014年2月至2016年2月烟台市中医医院收治的晚期肺腺癌患者90例进行研究分析。采用系统随机的方法分为对照组和观察组，每组45例。对照组采用安慰剂联合吉非替尼治疗，观察组采用矾贝散结颗粒辅助EGFR-TKI靶向治疗。观察2组患者后的短期疗效、生存周期、不良反应及生命质量改善情况，并观察患者治疗前后免疫功能指标的表达。结果：治疗后，观察组的有效率及控制率均高于对照组，但差异无统计学意义（P>0.05）；观察组稳定率为55.55%，明显高于对照组的22.22%，差异有统计学意义（P<0.05）。治疗前，2组患者免疫功能表达水平比较，差异无统计学意义（P>0.05）。治疗后，2组患者免疫功能表达水平较治疗前显著改善，差异无统计学意义（P<0.05），且观察组免疫功能表达水平改善优于对照组（P<0.05）。治疗后，观察组生命质量的改善率为80%，明显高于对照组的35.55%（P<0.05）。观察组24个月内生存率为66.67%，明显高于对照组的33.33%（P<0.05）。2组不良反应的发生情况比较，差异无统计学意义（P>0.05）。结论：矾贝散结颗粒辅助EGFR-TKI靶向对晚期肺腺癌进行治疗，疗效显著，可以有效改善患者的免疫功能及生命质量，提高患者的生存周期，减少患者不良反应的发生。 |
| English Summary: |
| To explore the clinical efficacy of Fanbei Sanjie Granule assisted EGFR-TKI on advanced lung adenocarcinoma and effects on immune function. Methods:Clinical data of 90 cases with advanced lung adenocarcinoma that were treated in our hospital from February 2014 to February 2016 were studied. According to random number table, they were divided into control group and treatment group, with 45 cases in each group. The control group was treated with placebo in combination with gefitinib. The treatment group was treated with Fanbei Sanjie granules and EGFR-TKI targeting. The short-term curative effect, survival cycle, adverse reaction and quality of life improvement of the two groups were observed, and the expression level of immune function before and after treatment was observed. Results:After treatment, the effective rate and control rate of the treatment group were higher than those of the control group, and the difference was not significant (P>0.05). The stability rate of the treatment group was 55.55%, which was significantly higher than that of the control group (22.22%). There was significant difference between the two groups (P<0.05). There was no significant difference in the expression of immune function between the two groups before treatment (P>0.05). After treatment, the expression of immune function in the two groups was significantly improved (P<0.05), and the improvement of the expression of immune function in the observation group was significantly better than that in the control group (P<0.05). After treatment, the improvement rate of quality of life in the treatment group was 80%, which was significantly higher than that in the control group (35.55%), and there was significant difference between the two groups (P<0.05). The survival rate of the treatment group was 66.67% in the 24 months, which was significantly higher than that in the control group (33.33%) (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion:Fanbei Sanjie Granule assisted EGFR-TKI targeting in treating advanced lung adenocarcinoma has significant curative effect, which can effectively improve the patient's immune function and quality of life, improve the survival cycle of patients, and reduce the adverse reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
